GSK may not have been surprised its anti-TIM-3 drug couldn’t secure a phase 3 win based on how its pharma peers have struggled. (iStock / Getty Images Plus) GSK’s cobolimab has become the latest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results